ClinicalTrials.gg
CompletedNCT02013050Updated Aug 28, 2017Results posted

A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

A Phase 2 interventional study of SGX942 and Placebo in Oral Mucositis, sponsored by Soligenix. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-28.

Sponsored by Soligenix · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.

Enrollment
16th of 73
111 · median 60
Started
2013
with 3 others
Phase 2
33 of 80
2 open now
Registered
34th of 80
by date
Lead sponsor
2 of 80
Soligenix

Among the 80 studies in Stomatitis with a site in United States, this one is the 16th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2013, is one of 33 in phase 2, and was the 34th registered.

Stomatitis

307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.

Browse Stomatitis studies →

Open to participants now

12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Stomatitis with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.

03

Conditions studied

  • Oral Mucositis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven non- squamous cell carcinoma of the mouth or oropharynx and is planned to receive a standard course of concomitant CRT.
  • Patients who have received surgery are eligible if surgery is performed within 6 weeks prior to study initiation.
  • Planned to receive standard cisplatin chemotherapy administered either weekly or every third week.
  • Must be able to read and understand
  • Adequate methods for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Current mucositis.
  • Prior radiation to the head and neck.
  • Chemotherapy treatment within the previous 12 months.
  • Tumors of the lips, sinuses, salivary glands or nasopharynx.
  • Unknown primary tumor.
  • Stage 4c .
  • Evidence of significant hepatic, hematologic, or immunologic disease.
  • Women who are pregnant or breast-feeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Control

    Drug: Placebo

  • Experimental
    SGX942

    Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg

    Drug: SGX942

Interventions

06

What researchers measure

Primary outcomes

  1. Duration of Severe Oral Mucositis (SOM)

    Duration of SOM was defined as the number of days from the onset of SOM until resolution of SOM. If the patient did not meet the requirements for resolution of SOM by the 1-month follow up visit, he/she was considered censored at the 1-month follow-up visit (or point of discontinuation of the study, if the patient had discontinued prior to the end of planned treatment). Patients who did not experience SOM were assigned a duration of 0.01. OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4.

    Time frame: 4 weeks after end of therapy

Secondary outcomes

  1. Residual Severe Oral Mucositis (SOM)

    OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.

    Time frame: 4 weeks after end of therapy

  2. Duration of Severe Oral Mucositis (SOM)

    OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.

    Time frame: 4 weeks after end of therapy

  3. Incidence of Clinically Reported, Non-fungal Infections

    Time frame: 4 weeks after end of therapy

  4. Percent of Patients With RECIST 1.1 Classification of "Complete Response"

    The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows: Target Lesion : Complete Response (CR): All target lesions gone Partial Response (PR): \>30% decrease from Baseline Progressive Disease (PD): \>20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR Non-Target Lesion: Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions

    Time frame: 4 weeks after end of therapy

  5. Duration of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin

    Time frame: 4 weeks after end of therapy

  6. Incidence of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin

    Time frame: 4 weeks after end of therapy

  7. Survival

    Time frame: 12 months after end of therapy

  8. Percent of Patients With RECIST 1.1 Classification of "Complete Response"

    The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows: Target Lesion : Complete Response (CR): All target lesions gone Partial Response (PR): \>30% decrease from Baseline Progressive Disease (PD): \>20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR Non-Target Lesion: Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions

    Time frame: 12 months after end of therapy

07

Results

Posted Jul 31, 2017

Participant flow

Participant flow — Overall Study
MilestonePlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Started4241323
Completed3836319
Not completed4504

Outcome measures

PrimaryDuration of Severe Oral Mucositis (SOM)

Duration of SOM was defined as the number of days from the onset of SOM until resolution of SOM. If the patient did not meet the requirements for resolution of SOM by the 1-month follow up visit, he/she was considered censored at the 1-month follow-up visit (or point of discontinuation of the study, if the patient had discontinued prior to the end of planned treatment). Patients who did not experience SOM were assigned a duration of 0.01. OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4.

Time frame:
4 weeks after end of therapy
Reported as:
Median · days
Duration of Severe Oral Mucositis (SOM)
daysPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Duration of Severe Oral Mucositis (SOM)18 (5 to 36)9 (3 to 19)14 (0 to NA)22 (3 to 36)
SecondaryResidual Severe Oral Mucositis (SOM)

OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.

Time frame:
4 weeks after end of therapy
Reported as:
Number · percentage of participants
Residual Severe Oral Mucositis (SOM)
percentage of participantsPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Residual Severe Oral Mucositis (SOM)2163316
SecondaryDuration of Severe Oral Mucositis (SOM)

OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.

Time frame:
4 weeks after end of therapy
Reported as:
Median · WHO score * days
Duration of Severe Oral Mucositis (SOM)
WHO score * daysPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Duration of Severe Oral Mucositis (SOM)35.5 (0 to 222)21.8 (0 to 210)33.0 (0 to 84)46.5 (0 to 167)
SecondaryIncidence of Clinically Reported, Non-fungal Infections
Time frame:
4 weeks after end of therapy
Reported as:
Number · percentage of participants
Incidence of Clinically Reported, Non-fungal Infections
percentage of participantsPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Incidence of Clinically Reported, Non-fungal Infections4528021
SecondaryPercent of Patients With RECIST 1.1 Classification of "Complete Response"

The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows: Target Lesion : Complete Response (CR): All target lesions gone Partial Response (PR): \>30% decrease from Baseline Progressive Disease (PD): \>20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR Non-Target Lesion: Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions

Time frame:
4 weeks after end of therapy
Reported as:
Number · percentage of participants
Percent of Patients With RECIST 1.1 Classification of "Complete Response"
percentage of participantsPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Percent of Patients With RECIST 1.1 Classification of "Complete Response"39473321
SecondaryDuration of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin
Time frame:
4 weeks after end of therapy
Reported as:
Median · days
Duration of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin
daysPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Duration of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin30 (5 to 65)10 (0 to 19)14 (0 to NA)17 (0 to NA)
SecondaryIncidence of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin
Time frame:
4 weeks after end of therapy
Reported as:
Number · percentage of participants
Incidence of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin
percentage of participantsPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Incidence of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin82676780
SecondarySurvival
Time frame:
12 months after end of therapy
Reported as:
Number · percentage of participants
Survival
percentage of participantsPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Survival819310083
SecondaryPercent of Patients With RECIST 1.1 Classification of "Complete Response"

The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows: Target Lesion : Complete Response (CR): All target lesions gone Partial Response (PR): \>30% decrease from Baseline Progressive Disease (PD): \>20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR Non-Target Lesion: Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions

Time frame:
12 months after end of therapy
Reported as:
Number · percentage of participants
Percent of Patients With RECIST 1.1 Classification of "Complete Response"
percentage of participantsPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
Percent of Patients With RECIST 1.1 Classification of "Complete Response"53533353

Adverse events

Collected over From the time of enrollment up until four weeks (±5 days) following the last study drug treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo8/43 (18.6%)25/41 (61%)41/41 (100%)
1.5 mg/kg3/41 (7.3%)25/42 (59.5%)42/42 (100%)
3.0 mg/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
6.0 mg/kg4/24 (16.7%)16/23 (69.6%)23/23 (100%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
DysphagiaGastrointestinal disorders2/411/421/30/23
ThrombocytopeniaBlood and lymphatic system disorders0/410/420/33/23
NauseaGastrointestinal disorders2/412/420/33/23
VomitingGastrointestinal disorders4/413/420/30/23
DehydrationMetabolism and nutrition disorders0/414/420/32/23
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/411/420/32/23
Respiratory failureRespiratory, thoracic and mediastinal disorders0/411/420/32/23
Febrile neutropeniaBlood and lymphatic system disorders1/413/420/31/23
ConstipationGastrointestinal disorders2/410/420/30/23
Lobar pneumoniaInfections and infestations2/411/420/30/23
Most frequent other events
Showing 10 of 88
Most frequent other events
EventPlacebo1.5 mg/kg3.0 mg/kg6.0 mg/kg
DysphagiaGastrointestinal disorders11/4114/423/36/23
NauseaGastrointestinal disorders29/4131/423/320/23
Abdominal pain upperGastrointestinal disorders0/411/422/31/23
ConstipationGastrointestinal disorders23/4118/422/311/23
Dry mouthGastrointestinal disorders11/4114/422/37/23
VomitingGastrointestinal disorders15/4123/422/312/23
ChillsGeneral disorders2/412/422/32/23
FatigueGeneral disorders21/4123/422/312/23
Abnormal loss of weightMetabolism and nutrition disorders8/4113/422/310/23
DysgeusiaNervous system disorders11/4122/422/313/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo1.5 mg/kg3.0 mg/kg6.0 mg/kgTotal
<=18 years00000
Between 18 and 65 years313122084
>=65 years11101325
Sex: Female, Male
Sex: Female, Male(Participants)Placebo1.5 mg/kg3.0 mg/kg6.0 mg/kgTotal
Female992323
Male333212086
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo1.5 mg/kg3.0 mg/kg6.0 mg/kgTotal
Hispanic or Latino12036
Not Hispanic or Latino4038320101
Unknown or Not Reported11002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo1.5 mg/kg3.0 mg/kg6.0 mg/kgTotal
American Indian or Alaska Native00000
Asian10012
Native Hawaiian or Other Pacific Islander10001
Black or African American25029
White383632097
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Placebo1.5 mg/kg3.0 mg/kg6.0 mg/kgTotal
United States4241323109
08

Study locations

1 site
  • Markey Cancer Center-University of Kentucky
    Lexington, Kentucky 40536, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Dec 2015 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2013
First posted
Dec 17, 2013
Start
Dec 2013
Primary completionActual
Dec 2015
CompletionActual
Sep 2016
Results first posted
Jul 31, 2017
Last update
Aug 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02013050
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Dec 2013
Primary completion
Dec 2015
Completion
Sep 2016
Results posted
Jul 31, 2017
Last update
Aug 28, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dusquetide

Start the discussion